Thus, large-scale studies on pharmacogenetic analyses are required to understand how polymorphisms affecting the EGFR/PI3K/PTEN/Akt/mTOR pathway could open possibilities for pharmacotherapy precision in BC [8, 47]. Here, AKT1 is linked to breast cancer.